Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PTGIR | P43119 | 6/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22329120 | 0.85 | CYP3A4 (0.31) | CYP3A4CYP1A2CYP2D6PTGIR | |
| SCHEMBL8948744 | 0.83 | CYP3A4 (0.51) | CYP3A4CYP1A2CYP2D6PTGIRCHRM2 | |
| SCHEMBL8948673 | 0.81 | SMN1; SMN2 (0.47) | PTGIRITGB3ITGA2BSMN1; SMN2CHRM3 | |
| SCHEMBL22565682 | 0.79 | KMT2A (0.41) | CYP3A4CYP1A2CYP2D6ITGB3ITGA2B | |
| SCHEMBL21191254 | 0.79 | KHK (0.31) | ITGB3ITGA2B | |
| SCHEMBL23996178 | 0.78 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL21405261 | 0.77 | PTGIR (0.35) | PTGIRITGB3ITGA2BPDK2 | |
| SCHEMBL20722066 | 0.76 | PDK2 (0.38) | PTGIRITGB3ITGA2BPDK2 | |
| SCHEMBL20179858 | 0.74 | ITGB3 (0.35) | CYP1A2PTGIRITGB3ITGA2BPDK2 | |
| SCHEMBL8948647 | 0.74 | ATM (0.52) | PTGIRITGB3ITGA2BSMN1; SMN2PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166954-B2 | Dihydropyrimidine compound and preparation method and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-5532255-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166954-B2 | Dihydropyrimidine compound and preparation method and use thereof | DPYD, DHPS, HPRT1 | CYP3A4 139/4885CYP1A2 195/4885CYP2D6 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.